Kerstin N. Vokinger

Apr 7, 2024 | jamanetwork.com | Aaron S. Kesselheim |Kerstin N. Vokinger |Thomas Hwang

Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs Renata Iskander, MSc; Hannah Moyer, MSc; Karine Vigneault, BSc; Salaheddin M. Mahmud, MD, PhD; Jonathan Kimmelman, PhD Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization Kerstin N. Vokinger, MD, JD, PhD, LLM; Aaron S.

Jun 28, 2023 | thelancet.com | Kristina Jenei |Mark P. Lythgoe |Kerstin N. Vokinger

The figure shows a cross-sectional analysis of the number of drug presentations that are discontinued or in shortage, or both, as a proportion of the total number of formulations authorised on the US market per high value cancer drug (NCCN category 1). These shortages represent a summary of evidence from the FDA website (US FDA Drug Shortages Database and the US FDA Approved Drug Products with Therapeutic Equivalence Evaluations [FDA Orange Book]).